Voyager Pharmaceuticals says it has completed enrollment for the first stage of its tests involving a potential drug for the treatment of Alzheimer’s.

The company plans to begin tests of its Durin implant, which Voyager has filed an investigational drug application with the FDA to cover, later this year.

Healthy volunteers will be tested first, the company said.

“The full enrollment of this study brings Voyager closer to introducing an innovative long-term care therapy for Alzheimer’s patients,” said Patrick Smith, chief executive officer of Voyager, in a statement.